Can Tarsus Pharmaceuticals Justify Its Valuation Before the Launch Window Closes?

Tarsus Pharmaceuticals (TARS) reports first-quarter 2026 earnings tomorrow, May 6th, after the market close, with analysts expecting a loss of $-0.43 per share. The central question for investors: can the commercial momentum behind XDEMVY—the company's FDA-approved treatment for Demodex blepharitis—continue to drive revenue growth and narrow losses faster than expected? With the stock trading at $65.04 and analysts projecting a dramatic swing to profitability in 2027, this report will test whether Tarsus can sustain its trajectory from niche biotech to commercial-stage revenue generator.

Part 1: Earnings Preview

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for eye care, with its lead product XDEMVY representing the first and only FDA-approved treatment for Demodex blepharitis. The company also has a pipeline including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, positioning it as a specialized player in ophthalmology and infectious disease.

Tarsus reports Q1 2026 earnings on May 6th after the close, with the consensus calling for a loss of $-0.43 per share. The most recent quarter (Q4 2025) delivered a loss of $-0.20 per share, representing significant improvement from the prior year. Compared to Q1 2025's loss of $-0.64 per share, the current estimate implies +32.81% year-over-year improvement, reflecting expectations that XDEMVY's commercial ramp is accelerating and operating leverage is beginning to materialize.

Three key themes define this earnings story:

XDEMVY Commercial Execution: The primary focus is prescription growth, market penetration, and physician adoption rates for XDEMVY. Investors will scrutinize revenue trajectory, payer coverage expansion, and any updated guidance on the commercial launch—management commentary on sales force effectiveness and market education efforts will be critical in assessing whether the company can sustain its revenue ramp and justify its $2.8 billion market cap.

Path to Profitability: With analysts projecting a dramatic swing to $2.62 EPS in 2027 (a +454% improvement from 2026's expected $-0.74 loss), this report will test whether the company's operating leverage story is on track. Investors need evidence that revenue growth is outpacing expense growth and that the timeline to sustained profitability remains credible—any changes to cash burn guidance or R&D spending will be closely watched.

Pipeline Progress and Strategic Positioning: Updates on TP-04 (Phase 2 for ocular rosacea) and TP-05 (Phase 2 for Lyme disease prevention) will signal whether Tarsus can diversify beyond XDEMVY. Any partnership announcements, international expansion plans, or competitive landscape commentary will help investors assess the company's long-term growth potential beyond its flagship product.

Analyst sentiment heading into the report is overwhelmingly bullish, with 9 of 11 analysts rating the stock a Strong Buy and a mean price target of $90.78 implying +39.6% upside. Oppenheimer recently raised its target to $105, citing confidence in XDEMVY's commercial trajectory and the company's ability to execute on its broader pipeline. However, the stock has underperformed recently—down from its 52-week high of $85.25—suggesting some investors are taking a wait-and-see approach ahead of this critical update.

Part 2: Historical Earnings Performance

Tarsus has delivered a mixed but improving earnings track record over the past four quarters. The company beat estimates in three of the last four reports, with surprises of +7.25% (Q1 2025), +14.29% (Q3 2025), and a modest -5.26% miss in Q4 2025. The notable exception was Q2 2025's -45.45% miss, when the company reported a loss of $-0.48 versus expectations of $-0.33—a significant disappointment that likely reflected higher-than-expected commercial launch expenses or slower-than-anticipated revenue ramp.

The trend is clearly toward narrowing losses. Reported EPS improved from $-0.64 in Q1 2025 to $-0.20 in Q4 2025, demonstrating meaningful progress as XDEMVY revenue scales. The year-over-year comparison is even more striking: Q1 2025's $-0.64 loss versus the current $-0.43 estimate for Q1 2026 represents a +32.81% improvement, while the prior-year Q4 comparison shows losses narrowing from $-0.69 to $-0.20.

The pattern suggests Tarsus is in a transitional phase where commercial execution matters more than ever. When the company beats estimates, it's typically by modest margins (5–15%), indicating analysts are tracking the business closely and estimates are reasonably calibrated. The Q2 2025 miss stands out as an outlier, likely tied to one-time launch costs or timing issues. Investors should watch whether Q1 2026 continues the sequential improvement trend or whether the company faces new headwinds in scaling XDEMVY's commercial operations.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Tarsus typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results drop, while Day +1 captures the market's first full reaction to the actual numbers.

Tarsus exhibits significant post-earnings volatility, with an average absolute Day 0 move of 3.58% and Day +1 move of 7.42%—well above typical biotech sector norms. The Day +1 range averages 10.27%, indicating the stock can swing dramatically as investors digest results and management commentary.

The direction of moves has been inconsistent, reflecting the market's uncertainty about the company's commercial trajectory. The most recent report (February 2026) saw a +4.47% Day 0 move followed by a +7.79% Day +1 gain, suggesting positive reception to Q4 results. However, the prior quarter (November 2025) delivered a +2.45% Day 0 pop that reversed to a -4.62% Day +1 decline, indicating initial optimism gave way to disappointment upon closer inspection.

The largest moves came during the commercial launch phase: August 2025 saw a +15.15% Day +1 surge (likely on strong early XDEMVY traction), while February 2025 delivered a -9.33% Day 0 drop (possibly reflecting launch cost concerns or slower-than-expected uptake). More recent volatility has moderated somewhat, but the 7–10% average range suggests investors should brace for meaningful price action regardless of whether the company beats or misses estimates. The key driver appears to be forward guidance and management commentary on XDEMVY's commercial momentum rather than the headline EPS number itself.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.06% for the May 15th expiration (10 days out), which aligns closely with the stock's 7.42% average Day +1 move and 10.27% average Day +1 range from historical earnings. This suggests options traders are anticipating typical volatility for a Tarsus earnings event—meaningful but not extreme. Investors using options strategies should note the implied move is well-calibrated to recent history, offering neither a significant premium nor discount relative to past post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment on Tarsus is overwhelmingly bullish, with a consensus rating of 4.64 out of 5.00—firmly in Strong Buy territory. The breakdown shows 9 Strong Buys, 0 Moderate Buys, 2 Holds, and no Sell ratings, reflecting broad confidence in the company's commercial execution and pipeline potential. The average price target of $90.78 implies +39.6% upside from the current $65.04 price, with a high target of $100.00 suggesting some analysts see even greater potential if XDEMVY adoption accelerates.

Sentiment has remained unchanged over the past month, with the same 4.64 rating and identical distribution of recommendations. This stability suggests analysts are waiting for fresh data from the Q1 report before adjusting their views—no major upgrades or downgrades have occurred recently, indicating the Street is comfortable with its current thesis but wants confirmation that the commercial trajectory remains on track.

The price target range is relatively tight ($68.00 to $100.00), with the low target still implying +4.5% upside from current levels. This narrow dispersion reflects consensus around the bull case: analysts broadly agree XDEMVY has significant commercial potential, and the debate centers on execution speed rather than fundamental viability. The fact that even the most conservative analyst sees upside underscores the Street's confidence that Tarsus is undervalued relative to its near-term earnings power and 2027 profitability outlook. However, the lack of recent rating changes also suggests analysts are in show-me mode—they need evidence from this earnings report that the path to profitability is accelerating as projected.

Part 4: Technical Picture

Tarsus enters earnings with a deteriorating technical setup, as the Barchart Technical Opinion has shifted from a 24% Buy signal one month ago to a 56% Sell signal currently—a significant reversal that persisted through last week's reading. This swing reflects growing near-term weakness as the stock has pulled back from higher levels, with momentum indicators turning negative.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, suggesting recent price action favors sellers
• Medium-term (50% Sell): Moderate sell signal reflects weakness in the intermediate timeframe, with the stock struggling to hold key support levels
• Long-term (50% Sell): Moderate sell signal shows longer-term trend has also deteriorated, indicating broader technical damage

Trend Characteristics: The signal strength is classified as Weak and the direction is Weakening, suggesting the technical environment is fragile heading into earnings—momentum is negative but not yet decisively bearish, leaving room for a strong earnings report to reverse the trend.

The stock is trading at $65.04, positioned above its 5-day ($63.50) and 10-day ($62.64) moving averages but below its 20-day ($66.35), 50-day ($68.80), 100-day ($70.83), and 200-day ($66.33) averages. This configuration indicates a short-term bounce within a broader downtrend—the stock has stabilized after recent weakness but remains under pressure from overhead resistance at multiple timeframes. The fact that price is hovering right around the 200-day moving average suggests this is a critical technical juncture: a strong earnings beat could propel TARS back above $66–$67 and shift momentum, while a disappointment could trigger a retest of the $60–$62 support zone established by the short-term averages. The overall setup is cautiously negative—technical indicators are flashing warning signs, but the stock's proximity to long-term support means a positive fundamental catalyst could quickly reverse the damage. Investors should watch whether TARS can reclaim the 20-day and 50-day averages in the sessions following the report, as that would signal a meaningful shift back toward bullish momentum.